Filtered By:
Condition: Bleeding
Management: WHO

This page shows you your search results in order of date.

Order by Relevance | Date

Total 18 results found since Jan 2013.

What Sub-Saharan African Nations Can Teach the U.S. About Black Maternal Health
While poor maternal outcomes among Black women in the U.S. is not new, improving it is imperative. U.S. policymakers can look to sub-Saharan Africa for guidance on reversing this trend. Credit: Ernest Ankomah/IPSBy Ifeanyi NsoforABUJA, Jun 2 2023 (IPS) New research shows that Black mothers in the United States disproportionately live in counties with higher maternal vulnerability and face greater risk of preterm death for the fetus, greater risk of low birth weight for a baby, and a higher number of maternal deaths. While poor maternal outcomes among Black women in the U.S. is not new, improving it is imperative. U.S. poli...
Source: IPS Inter Press Service - Health - June 2, 2023 Category: International Medicine & Public Health Authors: Ifeanyi Nsofor Tags: Africa Gender Headlines Health Inequality North America Poverty & SDGs Maternal Health Source Type: news

Antithrombotic treatment after stroke due to intracerebral haemorrhage
CONCLUSIONS: We did not identify beneficial or hazardous effects of short-term prophylactic dose parenteral anticoagulation and long-term oral antiplatelet therapy after ICH on important outcomes. Although there was a significant reduction in MACE and all major occlusive vascular events after long-term treatment with therapeutic dose oral anticoagulation for atrial fibrillation after ICH, the pooled estimates were imprecise, the certainty of evidence was only moderate, and effects on other important outcomes were uncertain. Large RCTs with a low risk of bias are required to resolve the ongoing dilemmas about antithrombotic...
Source: Cochrane Database of Systematic Reviews - January 26, 2023 Category: General Medicine Authors: Alexia Cochrane Chen Chen Jacqueline Stephen Ole Morten R ønning Craig S Anderson Graeme J Hankey Rustam Al-Shahi Salman Source Type: research

Antiplatelet agents and anticoagulants for hypertension
CONCLUSIONS: There is no evidence that antiplatelet therapy modifies mortality in patients with elevated BP for primary prevention. ASA reduced the risk of cardiovascular events and increased the risk of major bleeding events. Antiplatelet therapy with ASA probably reduces the risk of non-fatal and all cardiovascular events when compared to clopidogrel. Clopidogrel increases the risk of major bleeding events compared to ASA in patients with elevated BP for secondary prevention. There is no evidence that warfarin modifies mortality in patients with elevated BP for secondary prevention. The benefits and harms of the newer dr...
Source: Cochrane Database of Systematic Reviews - July 28, 2022 Category: General Medicine Authors: Eduard Shantsila Monika Kozie ł-Siołkowska Gregory Yh Lip Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Tips to reduce stroke in the diverse communities
Stroke is the second-leading cause of death worldwide, according to the World Health Organization. In the U.S., about 800,000 strokes occur per year. Of all strokes, 87% are ischemic. This means they occur when a clot blocks a blood vessel in the brain and stops blood flow. The remaining 13% are hemorrhagic, where a blood vessel ruptures and causes bleeding into brain tissue."In the U.S., stroke has dropped to the fifth-leading cause of death, due…
Source: News from Mayo Clinic - May 10, 2022 Category: Databases & Libraries Source Type: news

Editorial Commentary: The Current Evidence in Support of Tranexamic Acid in Arthroscopic Surgery Is Poor
Tranexamic acid (TXA) has been used to treat severe bleeding events for nearly 60 years and is on the list of World Health Organization essential medicines. Initially, it was described to treat heavy menstrual bleeding, but it is now used for a variety of applications. In orthopedic surgery, TXA is commonly used to reduce bleeding after total joint arthroplasty and spine surgery. The use of TXA for joint arthroplasty has been principally endorsed by various orthopedic societies, but they have also criticized a lack of evidence for high-risk patients with a history of pulmonary embolus, vascular stents, stroke, transient is...
Source: Arthroscopy - Journal of Arthroscopic and Related Surgery - February 1, 2022 Category: Surgery Authors: Erik Hohmann Tags: Editorial Commentary Source Type: research

Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in people with low surgical risk.
CONCLUSIONS: Our meta-analysis indicates that, in the short term, TAVI probably has little or no mortality difference compared to SAVR for severe AS in individuals with low surgical risk. Similarly, there is probably little or no difference in risk of stroke, MI, and cardiac death between the two approaches. TAVI may reduce the risk of rehospitalisation, but we are uncertain about the effects on LOS. TAVI reduces the risk of atrial fibrillation, AKI, and bleeding. However, this benefit is offset by the increased risk of PPM implantation. Long-term follow-up data are needed to further assess and validate these outcomes, esp...
Source: Cochrane Database of Systematic Reviews - December 19, 2019 Category: General Medicine Authors: Kolkailah AA, Doukky R, Pelletier MP, Volgman AS, Kaneko T, Nabhan AF Tags: Cochrane Database Syst Rev Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Platelet Count Predicts Adverse Clinical Outcomes After Ischemic Stroke or TIA: Subgroup Analysis of CNSR II
Conclusion: In ischemic stroke or TIA patients with platelet count within normal range, platelet count may be a qualified predictor for long-term recurrent stroke, mortality, and poor functional outcome. Introduction Platelets exert a critical role in the pathogenesis of atherosclerotic complications of cardio-cerebrovascular disease, contributing to thrombus formation, and embolism (1, 2). Previous literature reported that platelets of various size and density are produced by megakaryocytes of different size and stages of maturation in different clinical conditions, suggesting various platelet patterns in differen...
Source: Frontiers in Neurology - April 11, 2019 Category: Neurology Source Type: research

Impact of anemia on percutaneous coronary intervention in Chinese patients: A large single center data
ConclusionsPre ‐PCI anemia was not an independent risk factor of any adverse clinical events, while post‐PCI anemia had a predictable value of MI, TVR, and MACE after PCI.
Source: Journal of Interventional Cardiology - December 5, 2018 Category: Cardiology Authors: Lin Jiang, Zhan Gao, Ying Song, Jingjing Xu, Xiaofang Tang, Huanhuan Wang, Ru Liu, Ping Jiang, Bo Xu, Jinqing Yuan Tags: ORIGINAL INVESTIGATION Source Type: research

Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.
CONCLUSIONS: This is the most extensive systematic review of RCTs conducted to date to assess effects of increasing PUFA on cardiovascular disease, mortality, lipids or adiposity. Increasing PUFA intake probably slightly reduces risk of coronary heart disease and cardiovascular disease events, may slightly reduce risk of coronary heart disease mortality and stroke (though not ruling out harms), but has little or no effect on all-cause or cardiovascular disease mortality. The mechanism may be via TG reduction. PMID: 30484282 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - November 27, 2018 Category: General Medicine Authors: Abdelhamid AS, Martin N, Bridges C, Brainard JS, Wang X, Brown TJ, Hanson S, Jimoh OF, Ajabnoor SM, Deane KH, Song F, Hooper L Tags: Cochrane Database Syst Rev Source Type: research

Impact of anemia on percutaneous coronary intervention in Chinese patients: A large single center data
ConclusionsPre ‐PCI anemia was not an independent risk factor of any adverse clinical events, while post‐PCI anemia had a predictable value of MI, TVR, and MACE after PCI.
Source: Journal of Interventional Cardiology - November 22, 2018 Category: Cardiology Authors: Lin Jiang, Zhan Gao, Ying Song, Jingjing Xu, Xiaofang Tang, Huanhuan Wang, Ru Liu, Ping Jiang, Bo Xu, Jinqing Yuan Tags: ORIGINAL INVESTIGATION Source Type: research

Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.
CONCLUSIONS: This is the most extensive systematic review of RCTs conducted to date to assess effects of increasing PUFA on cardiovascular disease, mortality, lipids or adiposity. Increasing PUFA intake probably slightly reduces risk of coronary heart disease and cardiovascular disease events, may slightly reduce risk of coronary heart disease mortality and stroke (though not ruling out harms), but has little or no effect on all-cause or cardiovascular disease mortality. The mechanism may be via lipid reduction, but increasing PUFA probably slightly increases weight. PMID: 30019767 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - July 18, 2018 Category: General Medicine Authors: Abdelhamid AS, Martin N, Bridges C, Brainard JS, Wang X, Brown TJ, Hanson S, Jimoh OF, Ajabnoor SM, Deane KH, Song F, Hooper L Tags: Cochrane Database Syst Rev Source Type: research

Impact of anemia on in ‐hospital complications after ischemic stroke
ConclusionAnemia is an independent predictor of in‐hospital complications following stroke, especially for pneumonia, GIB and thromboembolism. Whether prophylaxis and treatment of anemia would prevent in‐hospital complications remains to be studied.This article is protected by copyright. All rights reserved.
Source: European Journal of Neurology - February 12, 2018 Category: Neurology Authors: Chen ‐Chen Wei, Shu‐Ting Zhang, Ge Tan, Shi‐Hong Zhang, Ming Liu Tags: Original Article Source Type: research